- Home
- EDTK vs RLYB Comparison
EDTK vs RLYB Comparison
Compare EDTK & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- RLYB
- Stock Information
- Founded
- EDTK 2013
- RLYB 2018
- Country
- EDTK China
- RLYB United States
- Employees
- EDTK N/A
- RLYB N/A
- Industry
- EDTK Other Consumer Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- RLYB Health Care
- Exchange
- EDTK Nasdaq
- RLYB Nasdaq
- Market Cap
- EDTK 14.3M
- RLYB 14.4M
- IPO Year
- EDTK 2020
- RLYB 2021
- Fundamental
- Price
- EDTK $0.93
- RLYB $0.41
- Analyst Decision
- EDTK
- RLYB Hold
- Analyst Count
- EDTK 0
- RLYB 3
- Target Price
- EDTK N/A
- RLYB $15.00
- AVG Volume (30 Days)
- EDTK 8.7K
- RLYB 8.1M
- Earning Date
- EDTK 08-18-2025
- RLYB 08-07-2025
- Dividend Yield
- EDTK N/A
- RLYB N/A
- EPS Growth
- EDTK N/A
- RLYB N/A
- EPS
- EDTK N/A
- RLYB N/A
- Revenue
- EDTK $624,365.00
- RLYB $848,000.00
- Revenue This Year
- EDTK N/A
- RLYB N/A
- Revenue Next Year
- EDTK N/A
- RLYB N/A
- P/E Ratio
- EDTK N/A
- RLYB N/A
- Revenue Growth
- EDTK N/A
- RLYB N/A
- 52 Week Low
- EDTK $0.80
- RLYB $0.22
- 52 Week High
- EDTK $1.27
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- EDTK 54.77
- RLYB 55.26
- Support Level
- EDTK $0.87
- RLYB $0.32
- Resistance Level
- EDTK $0.95
- RLYB $0.61
- Average True Range (ATR)
- EDTK 0.05
- RLYB 0.05
- MACD
- EDTK 0.01
- RLYB 0.01
- Stochastic Oscillator
- EDTK 100.00
- RLYB 34.82
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.